News Sentiment

ANVS sentiment intelligence

Annovis Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 62 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.86 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.6% over one week, +4.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -3.6% Price reacting lower
Trend fit Trend inactive 4.5% over four weeks
Fair value -68.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingView 7
Investing.com 7
GlobeNewswire 5
The Globe and Mail 3
Moomoo 3
ad-hoc-news.de 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 18
Regulatory and legal 4
Analyst action 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Investing.com Direct company coverage

Annovis Bio shareholders approve all proposals at annual meeting

Annovis Bio, Inc. shareholders approved all proposals at their 2026 Annual Meeting. Key approvals included the re-election of five directors, the ratification of Ernst & Young LLP as auditors, and an amendment to the 2019 Equity Incentive Plan to increase issuable shares. Shareho

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:39
Source
Investing.com
TradingKey Direct company coverage

Annovis Bio Inc (ANVS) Institutional Confidence

This article from TradingKey provides an overview of Annovis Bio Inc (ANVS) with a specific focus on "Institutional Confidence." It lists key institutional shareholders and their recent activity, including shares held and percentage change. The data highlights significant increas

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:39
Source
TradingKey
Stock Titan Direct company coverage

Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay

Annovis Bio (NYSE: ANVS) stockholders approved all five proposals at their 2026 Annual Meeting. Key approvals include the election of five directors, ratification of Ernst & Young LLP as auditor, and an amendment to the 2019 Equity Incentive Plan to increase available shares. Sto

Tone
Positive 64/100
Event
Market update
Published
17 Jun 2026 20:39
Source
Stock Titan